Mebendazole

證據等級: L5

預測適應症: 10 個

Mebendazole: From Intestinal Helminth Infections to Echinococcosis

One-Sentence Summary

Mebendazole is a benzimidazole anthelmintic established for treating intestinal parasitic worm infections, including roundworm, whipworm, hookworm, and pinworm. The TxGNN model identifies Alveolar Echinococcosis as the most evidentially supported predicted indication, with 1 clinical trial and 20 publications currently providing supporting data — consistent with Mebendazole’s WHO-recognized role as an established alternative benzimidazole therapy for echinococcosis. However, Mebendazole is not currently registered in India, and pharmacokinetic challenges related to oral bioavailability remain a practical barrier for echinococcosis treatment.

Quick Overview

Item	Content
Original Indication	Intestinal parasitic infections (ascariasis, trichuriasis, hookworm, enterobiasis / pinworm)
Predicted New Indication	Alveolar Echinococcosis (Echinococcus multilocularis infection)
TxGNN Prediction Score	94.2%
Evidence Level	L3
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

All TxGNN Predicted Indications

This Evidence Pack covers 10 predicted indications for Mebendazole. The table below summarizes all predictions ranked by TxGNN score.

Rank	Indication	TxGNN Score	Evidence Level	Mechanistic Link	Recommendation
1	Acne (disease)	99.2%	L5	None — graph proximity artifact, no biological basis	Hold
2	Leishmaniasis, diffuse cutaneous	98.4%	L5	Weak indirect (Leishmania carries β-tubulin but structural differences limit applicability)	Hold
3	Echinococcus granulosus infectious disease	95.6%	L3	Direct — established benzimidazole anti-tubulin mechanism	Proceed with Guardrails
4	Hordeolum	94.9%	L5	None — staphylococcal eyelid infection, bacterial etiology unrelated	Hold
5	Alveolar echinococcosis	94.2%	L3	Direct — established benzimidazole anti-tubulin mechanism	Proceed with Guardrails
6	Inhalational botulism	93.8%	L5	None — neurotoxin-mediated mechanism has no connection to anthelmintics	Hold
7	Toxin-mediated infectious botulism	93.5%	L5	None — same neurotoxin rationale as above	Hold
8	Impetigo	93.2%	L5	None — gram-positive bacterial skin infection unrelated	Hold
9	Sorsby’s fundus dystrophy	93.1%	L5	None — TIMP3 genetic retinal disease has no pharmacological connection	Hold
10	Demodicidosis of sebaceous gland	93.0%	L5	Weak indirect (Demodex is an arthropod with tubulin, but standard treatments are ivermectin/permethrin)	Hold

Key finding: Among all 10 TxGNN predictions, only Echinococcus granulosus (rank 3) and Alveolar echinococcosis (rank 5) carry direct mechanistic support and clinical literature evidence. The top-scoring prediction (acne, 99.2%) reflects knowledge graph structural proximity rather than true drug-disease biology, and is not supported by any mechanistic or clinical data.

Why is This Prediction Reasonable?

Currently, detailed mechanism of action (MOA) data is not available in this Evidence Pack. Based on established pharmacology, Mebendazole is a benzimidazole-class anthelmintic that selectively binds β-tubulin in helminths and inhibits tubulin polymerization, preventing microtubule assembly. This disrupts the parasite’s cytoskeletal integrity, blocks glucose uptake, and ultimately causes parasite immobilization and death. The key feature of this mechanism is its selectivity for helminth tubulin over mammalian tubulin at therapeutic doses.

Both Echinococcus granulosus (causing cystic echinococcosis, CE) and Echinococcus multilocularis (causing alveolar echinococcosis, AE) are cestode tapeworms whose larval metacestode stages carry β-tubulin susceptible to benzimidazole inhibition. For CE, mebendazole impairs protoscolex viability and germinal layer integrity of hydatid cysts. For AE — the more dangerous form, with infiltrative growth resembling cancer — mebendazole inhibits vesicular metacestode budding and proliferation by the same mechanism. WHO guidelines have formally recognized both albendazole and mebendazole as the standard benzimidazole chemotherapy options for echinococcosis since the 1990s. Albendazole is preferred due to superior oral bioavailability and tissue penetration, but mebendazole is an established, guideline-endorsed alternative.

The mechanistic bridge from intestinal nematode treatment to echinococcal cestode disease is pharmacologically coherent — the anti-tubulin target is conserved across helminth classes. The defining challenge for echinococcosis specifically is the need for high, sustained plasma mebendazole concentrations (target >0.25 µmol/L) to reach tissue-embedded metacestodes, a pharmacokinetic requirement that demands therapeutic drug monitoring (TDM). This is especially important when CYP-inducing antiepileptic drugs such as carbamazepine, phenytoin, or phenobarbital are co-prescribed, as these can significantly reduce plasma mebendazole levels and undermine efficacy.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02876146	Observational	Completed	50	EchinoVISTA: Prospective study of hepatic AE patients treated with benzimidazoles (primarily albendazole); evaluated parasite viability biomarkers and imaging follow-up markers to optimize treatment withdrawal timing; provides a clinical monitoring framework directly applicable to mebendazole-treated AE patients

Literature Evidence

Alveolar Echinococcosis — 20 Publications Available (Top 10 Shown)

PMID	Year	Type	Journal	Key Findings
10980173	2000	Comparative Clinical Study	J Antimicrob Chemother	Open-label study of 35 AE patients followed for avg 39 months; mebendazole vs albendazole compared; treatment success (disease non-progression) demonstrated for both; foundational comparative efficacy data
7197224	1981	PK / Clinical Study	Eur J Clin Pharmacol	Plasma mebendazole concentration targets established: >0.25 µmol/L required for anti-echinococcal activity; underpins the TDM requirement for echinococcosis treatment
9875648	1998	Long-term Clinical Case	J Hepatology	13-year continuous mebendazole therapy (~45–48 mg/kg/day) in non-resectable AE patient; long-term therapy may achieve parasitocidal effect; demonstrates extended tolerability
16044412	2005	Clinical Cohort	Brit J Surgery	25-year prospective data comparing three AE treatment strategies: benzimidazole alone, curative resection + 2-year adjuvant, and partial debulking + continuous benzimidazole
8789923	1996	WHO Guidelines	Bull World Health Org	WHO Working Group guidelines: mebendazole and albendazole are recommended chemotherapy for CE and AE; perioperative and standalone use protocols defined
27686694	2016	Expert Review	Expert Rev Anti-Infect Ther	Current interventional strategy for hepatic AE; integrates surgical, percutaneous, and perendoscopic approaches with benzimidazole chemotherapy; hepatic resection preferred when feasible
39311470	2024	Review	Parasite (Paris)	Benzimidazoles (albendazole or mebendazole) remain the only recommended chemotherapy for AE; parasitostatic effect means treatment is typically lifelong; hepatotoxicity and drug interactions are key ongoing management concerns
39606163	2024	Review	World J Hepatol	AE drug therapy update; long incubation period leads to late diagnosis with complications; mebendazole and albendazole as primary pharmacotherapy; surgery + chemotherapy combination critical
19254162	2009	Consensus Review	Expert Rev Anti-Infect Ther	Expert consensus confirming mebendazole and albendazole as standard-of-care benzimidazoles for both CE and AE
40093668	2025	Review	World J Gastroenterol	Most recent comprehensive management review of liver echinococcosis; surgical removal is cornerstone; AE resembles carcinoma and is fatal without treatment; benzimidazoles essential as adjuvant

Echinococcus granulosus Infectious Disease — Key Supporting Publications

PMID	Year	Type	Journal	Key Findings
2585032	1989	Clinical Observational Series	J Chemotherapy	70 patients, 150 hydatid cysts treated with mebendazole per WHO protocol; 6 months–5 years follow-up; morphological or volumetric response observed in 64.3% of cysts; direct clinical efficacy evidence
24686032	2014	In Vitro Study	Int J Surgery	Selenium nanoparticles as scolicidal agents evaluated against CE; mebendazole and albendazole cited as established perioperative chemotherapy standard
39178325	2024	Experimental	PLoS Pathogens	Monoclonal antibody immunotherapy evaluated for echinococcosis; benzimidazoles acknowledged as current chemotherapy backbone with limited efficacy; novel combination approaches under development

India Market Information

Mebendazole is not registered or marketed in India. There are 0 approved product licenses in the Indian regulatory database. No authorized product information is available through Indian regulatory channels.

For patient access in India, physicians would need to evaluate importation authorization under applicable Indian regulations or seek institutional compassionate use pathways, referencing international approvals such as the WHO Essential Medicines List, US FDA, or EMA authorizations as supporting documentation.

Safety Considerations

Drug Interactions (10 interactions identified, source: DDInter):

Interacting Drug	Level	Clinical Note
Phenobarbital	Moderate	CYP inducer — substantially reduces mebendazole plasma levels; critical risk for echinococcosis treatment where TDM is required
Carbamazepine	Moderate	CYP inducer — same mechanism as phenobarbital; co-prescription warrants dose review
Phenytoin	Moderate	CYP inducer — reduces mebendazole levels; especially relevant in epilepsy patients with concurrent parasitic disease
Fosphenytoin	Moderate	Phenytoin prodrug — same CYP induction concern
Primidone	Moderate	Metabolized to phenobarbital — same CYP induction risk
Metronidazole	Moderate	Pharmacokinetic interaction; monitor when co-administering
Ritonavir	Moderate	CYP inhibitor — may increase mebendazole plasma levels; monitor for concentration-related toxicity
Iodide I-131	Moderate	Monitor when co-administering with radioiodine therapy
Iodide I-123	Moderate	Monitor when co-administering with radioiodine imaging procedures
Cimetidine	Minor	Minor pharmacokinetic interaction; generally manageable without dose adjustment

Clinical Priority for Echinococcosis Treatment: The interaction between mebendazole and antiepileptic CYP inducers (phenobarbital, carbamazepine, phenytoin, primidone) is the most clinically significant safety concern. These drugs can substantially reduce mebendazole plasma concentrations below the therapeutic threshold required for anti-echinococcal activity. Therapeutic drug monitoring (target plasma level ≥0.25 µmol/L) is strongly recommended when any of these agents are co-prescribed.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Mebendazole’s use for echinococcosis (CE and AE) is supported by WHO guidelines, multiple clinical observational studies, and extensive review literature (L3 evidence), representing a pharmacologically well-grounded extension of its established anti-tubulin mechanism into cestode larval disease — not a speculative repurposing hypothesis. The main barriers to use in India are the complete absence of local marketing authorization and the pharmacokinetic challenge of achieving and maintaining adequate plasma concentrations, particularly in patients on interacting medications.

To proceed, the following is needed:

Regulatory pathway assessment: Evaluate options for Indian registration, licensed importation authorization, or institutional compassionate use protocol for echinococcosis patients who have no other treatment options
Pharmacokinetic monitoring protocol: Establish mebendazole plasma concentration targets (≥0.25 µmol/L) and a TDM procedure feasible within Indian clinical settings; consider whether albendazole (higher bioavailability) is more practical as first-line
Drug interaction management plan: Screen all patients for concurrent CYP-inducing antiepileptics; establish dose adjustment criteria or alternative benzimidazole selection if significant interaction is identified
Hepatotoxicity monitoring schedule: Define liver function monitoring intervals (ALT, AST, bilirubin) for patients requiring long-term benzimidazole therapy
Safety gap remediation (DG001): Obtain and review full package insert including contraindications and warnings from a reference regulatory authority (e.g., US FDA, EMA)
MOA documentation (DG002): Retrieve complete mechanism of action data via DrugBank API to formalize the mechanistic analysis in this report
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.